Aktis Oncology, Inc. (AKTS)

US — Healthcare Sector
Peers:

Automate Your Wheel Strategy on AKTS

With Tiblio's Option Bot, you can configure your own wheel strategy including AKTS - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol AKTS
  • Rev/Share 0.0
  • Book/Share 0.0
  • PB 0.0
  • Debt/Equity -0.1368
  • CurrentRatio 15.9841
  • ROIC -0.1686

 

  • MktCap 1079858036.0
  • FreeCF/Share 0.0
  • PFCF 90.7444
  • PE 0.0
  • Debt/Assets 0.0368
  • DivYield 0
  • ROE 0.6559

 

  • Rating D+
  • Score 1
  • Recommendation Strong Sell
  • P/E Score 1
  • DCF Score 1
  • P/B Score 1
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
No ratings available.

News

A Fresh IPO That Long-Term Investors Shouldn't Ignore
AKTS
Published: January 14, 2026 by: MarketBeat
Sentiment: Neutral

For speculative investors, the start of each year is always a good time to revisit an initial public offering (IPO) calendar. Almost every week, companies go public, with a handful of them offering considerable short-term upside potential.

Read More
image for news A Fresh IPO That Long-Term Investors Shouldn't Ignore
Vida Ventures Congratulates Aktis Oncology on Its Entry into the Public Markets
AKTS, LLY
Published: January 09, 2026 by: Business Wire
Sentiment: Neutral

LOS ANGELES & BOSTON--(BUSINESS WIRE)--Vida Ventures (“Vida”), a next-generation life sciences venture firm, today congratulates Aktis Oncology (Nasdaq: AKTS), a clinical-stage biotechnology company advancing a pipeline of alpha-emitting radiopharmaceuticals for the treatment of solid tumors. Aktis raised $318 million in its initial public offering, reflecting strong investor interest, its recently announced anchor investment by Eli Lilly and Company (NYSE: LLY), and pipeline momentum as the co.

Read More
image for news Vida Ventures Congratulates Aktis Oncology on Its Entry into the Public Markets

About Aktis Oncology, Inc. (AKTS)

  • IPO Date 2026-01-09
  • Website https://www.aktisoncology.com
  • Industry Biotechnology
  • CEO Matthew Roden
  • Employees None
Aktis Oncology, Inc. operates as a clinical-stage oncology company that engages in the development of targeted radiopharmaceutical therapies for cancer treatment. The company offers a miniprotein radioconjugate platform to discover and develop radiopharmaceutical therapies that deliver the tumor-killing properties of radioisotopes. It offers Nectin-4, a miniprotein radioconjugate for the treatment of locally advanced or metastatic urothelial cancer. Its products include AKY-1189 to deliver a radioisotope to Nectin-4 expressing tumors for the treatment of metastatic urothelial cancer, breast cancer, NSCLC, colorectal cancer and cervical cancer; and AKY-2519 to deliver radioisotope to B7-H3 CD276 expressing tumors targeting prostate, lung and other solid tumors. The company was formerly known as HotKnot Therapeutics, Inc. and changed its name to Aktis Oncology, Inc. in April 2020. Aktis Oncology, Inc. was incorporated in 2020 and is based in Boston, Massachusetts.